Silence Therapeutics (NASDAQ:SLN) Shares Up 4%

Silence Therapeutics plc (NASDAQ:SLN) shares traded up 4% on Monday . The company traded as high as $19.65 and last traded at $19.65. 1,378 shares were traded during mid-day trading, a decline of 99% from the average session volume of 195,118 shares. The stock had previously closed at $18.90.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Thursday, June 20th. Chardan Capital reiterated a “buy” rating and set a $42.00 target price on shares of Silence Therapeutics in a research report on Friday, May 17th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $45.00 price target on shares of Silence Therapeutics in a research report on Monday, April 22nd.

Silence Therapeutics Price Performance

The firm has a fifty day moving average of $21.35 and a 200-day moving average of $20.95.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.18. The company had revenue of $15.73 million for the quarter, compared to analyst estimates of $4.53 million. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. Equities analysts anticipate that Silence Therapeutics plc will post -1.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SLN. SG Americas Securities LLC increased its holdings in Silence Therapeutics by 10.5% during the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after purchasing an additional 667 shares during the last quarter. Parkman Healthcare Partners LLC grew its position in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after buying an additional 40,063 shares in the last quarter. Lynx1 Capital Management LP bought a new stake in shares of Silence Therapeutics in the third quarter worth $2,315,000. Vivo Capital LLC acquired a new stake in Silence Therapeutics in the fourth quarter valued at $8,862,000. Finally, Janus Henderson Group PLC acquired a new stake in Silence Therapeutics in the first quarter valued at $13,575,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.